Skip to main content
SINPHAR logo

SINPHAR — Investor Relations & Filings

Ticker · 1734 ISIN · TW0001734002 TW Manufacturing
Open in API
Filings indexed 1,611 across all filing types
Latest filing 2024-03-26 Director's Dealing
Country TW Taiwan
Listing TW 1734

About SINPHAR

www.sinphar.com

Sinphar Pharmaceutical Co., Ltd. is a vertically integrated pharmaceutical group specializing in the research, development, manufacturing, and distribution of therapeutic medicines, nutraceuticals, and medical cosmetics. Established in 1977, the company produces a diverse range of products, including Western and Chinese pharmaceuticals, specialized oncology drugs, and health supplements. Sinphar operates advanced R&D facilities and an ISO 17025-certified laboratory, leveraging high-precision technology for product innovation and quality assurance. Its business model encompasses proprietary brand management alongside professional OEM and ODM services for international markets. Key areas of expertise include the development of cancer treatments, functional health foods, and medical-grade skincare. Through its global marketing network and dedicated retail counters, Sinphar provides comprehensive healthcare solutions focused on life, health, and technology.

Recent filings

Filing Released Lang Actions
113年03月內部人持股轉讓(事前)
Director's Dealing Classification · 100% confidence The document is a report of a director's personal share transaction, detailing the transfer of shares by a company director (郭修吉) including dates, share quantities, and transfer methods. It is a typical insider trading disclosure. There is no indication of financial results, management discussion, or other report types. The document matches the definition of Director's Dealing (DIRS). The document length is short and focused solely on insider share transactions, confirming the classification.
2024-03-26 Chinese
公告本公司配合檢調單位執行搜索調查
Legal Proceedings Report Classification · 95% confidence The document is a short announcement from a company (杏輝) regarding a search and investigation conducted by a regulatory authority (法務部調查局臺北市調查處) related to securities law. It states the company is cooperating with the investigation and that operations and finances are normal. There is no financial data, no report attached or referenced beyond the announcement of the investigation event. The document length is very short (563 characters), and it is clearly a regulatory announcement about a legal proceeding or investigation. Therefore, it fits best under Legal Proceedings Report (LTR).
2024-03-20 Chinese
112年度應收帳款周轉率
Fund Information / Factsheet Classification · 90% confidence The document is very short (281 characters) and contains financial ratios related to accounts receivable turnover and average collection days for two fiscal years (111 and 112). There is no detailed financial statement or comprehensive analysis, only a brief data table and a note about significant changes. This suggests it is a brief financial summary or fact sheet rather than a full report. Given the brevity and nature of the content, it fits best as a Fund Information / Factsheet (FS) rather than a full Annual Report or Interim Report. It is not an announcement or certification, so RPA or RNS are less appropriate.
2024-03-15 Chinese
112年度存貨週轉率
Regulatory Filings Classification · 95% confidence The document is very short (280 characters) and contains a brief table with inventory turnover rates and average sales days for two fiscal years (111 and 112). It includes a note about significant changes in inventory turnover rates. There is no detailed financial data, no comprehensive report, no management discussion, or any regulatory or legal content. The content is a simple disclosure of a specific financial metric without broader context or analysis. Given the brevity and nature of the content, it does not qualify as an Annual Report, Interim Report, or any detailed financial filing. It is more of a regulatory disclosure or announcement of a specific metric. Since it does not fit other categories and is a brief regulatory disclosure, the best fit is Regulatory Filings (RNS).
2024-03-15 Chinese
112年度毛利率
Fund Information / Factsheet Classification · 90% confidence The document contains a brief financial summary table showing annual revenue, cost, gross profit, and gross margin percentages for two consecutive years (111 and 112). The text mentions an update date (April 1) and includes a note about explaining significant changes in gross margin. The document length is very short (390 characters), and it does not contain detailed financial statements or comprehensive analysis. It appears to be a brief financial summary or factsheet rather than a full annual or interim report. There is no indication of it being an announcement or certification. Given the brevity and content, the best fit is Fund Information / Factsheet (FS), which covers brief summaries of key company financials and facts.
2024-03-15 Chinese
112年度營益分析
Interim / Quarterly Report Classification · 95% confidence The document contains financial data for multiple fiscal periods including quarterly (first quarter, half-year, third quarter) and full-year results. It includes detailed financial metrics such as operating revenue, gross margin, operating profit margin, pre-tax profit margin, and after-tax profit margin. The data spans multiple years and is presented in a tabular format. The document length is 1054 characters, which is relatively short but contains substantive financial data rather than just an announcement or a link to a report. The presence of quarterly and annual financial data with detailed metrics indicates this is a financial report for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report (IR).
2024-03-15 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.